Boro Dropulic

last updated 5/4/2018

Boro Dropulic

President and Chief Scientifc Offr at Lentigen Corporation

Location:
910 Clopper Road, Suite 200 S, Gaithersburg, Maryland, United States
HQ Phone:
(301) 527-4200

General Information

Experience

Chief Science Officer, Lentigen Technology - A Miltenyi Biotec Company

Contributor - PR Newswire

Instructor and Adjunct Assistant Professor - Johns Hopkins University

Education

B.Sc.University of Western Australia

MBAThe Johns Hopkins University

Ph.D.University of Western Australia

Affiliations

Member of the Infectious Diseases and Industrial Liaisons Committees - American Society of Gene Therapy

Board Member - Jadran d.d. Crikvenica

Scientific Advisory Board Member - GBP Capital

Founder and Chief Scientific Officer - VIRxSYS Corporation

Fogarty Research Associate - National Institute of Allergy and Infectious Diseases

Fogarty Fellow - National Institutes of Health

Member of the Editorial Board - Human Gene Therapy

Recent News  

Lentigen | Gene Delivery Systems

Boro Dropulic, Ph.D. M.B.A
Founder President and Chief Scientific Officer Dr. Dropulic has more than 20 years of experience in academia and the biotech industry. Prior to founding Lentigen, he was founder and chief scientific officer of ViRxSys where he successfully led a multidisciplinary team to initiate and complete the first lentiviral vector clinical trial in humans. Previously, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop an HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus. Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body. Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and an MBA from The Johns Hopkins University.

Read More
http://www.imapac.com/index.php?page=VaccineWorldCISCEESummit-Speakers

Boro Dropulic,
President and Chief Scientific Officer, Lentigen Corporation, USA

Read More
Lentigen | Gene Delivery Systems

Boro Dropulic, Ph.D. M.B.AFounderPresident and Chief Scientific OfficerDr. Dropulic is one of the leading experts in Lentiviral Vector technology.He is a member of the Infectious Diseases and Industrial Liaisons Committees for the American Society of Gene Therapy and a member of the Editorial Board of the journal Human Gene Therapy. Prior to founding Lentigen, he was Founder and Chief Scientific Officer of VIRxSYS where he successfully led a multidisciplinary team to initiate and complete the first ever Lentiviral Vector clinical trial in humans.Prior to founding VIRxSYS, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop a HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus. Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS.He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body.Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and a MBA from The Johns Hopkins University.

Read More

Browse ZoomInfo’s Directories